Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors, stimulants |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors), Apoptosis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationSpecial Review Project (China) |
Molecular FormulaC32H34O10 |
InChIKeyNIOHNDKHQHVLKA-UHFFFAOYSA-N |
CAS Registry866541-93-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Endometriosis | China | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Phase 2 | United States | 01 Nov 2005 | |
Recurrent Lung Small Cell Carcinoma | Preclinical | Ukraine | 01 Nov 2006 | |
Recurrent Lung Small Cell Carcinoma | Preclinical | United States | 01 Nov 2006 | |
Recurrent Lung Small Cell Carcinoma | Preclinical | Russia | 01 Nov 2006 | |
Castration-Resistant Prostatic Cancer | Preclinical | United States | 01 Dec 2005 | |
Chronic Lymphocytic Leukemia | Preclinical | United States | 01 Nov 2005 | |
Diffuse Large B-Cell Lymphoma | Preclinical | United States | 01 Nov 2005 | |
Follicular Lymphoma | Preclinical | United States | 01 Nov 2005 | |
Mantle-Cell Lymphoma | Preclinical | United States | 01 Nov 2005 | |
Small Lymphocytic Lymphoma | Preclinical | United States | 01 Nov 2005 |
Phase 1 | 24 | (ecljqzersc) = the MTD was not determined celirqknlc (yrmvgsvodv ) | Negative | 01 Jun 2020 | |||
Phase 1 | 10 | (bkprrxwbvw) = at 20 mg daily dose of AT-101 with 25 mg of R and 40 mg weekly :1 pt with febrile neutropenia and neutropenia lasting 9 days and 1 pt with thrombocytopenia lasting 8 days aqqedzrnji (hafmquzvzw ) View more | Positive | 13 Nov 2019 | |||
Phase 2 | 29 | (qsprirxnsr) = rlgpiyjjmn cvrnuwcmji (ukwwfnnwig ) | Negative | 01 Aug 2019 | |||
Phase 2 | 56 | laboratory biomarker analysis+R-(-)-gossypol acetic acid | (wobtnfuomx) = zkucvnfkbz djbqcajhwv (atmpqkudih, bmkrzppuij - jysxfycukd) View more | - | 12 Jul 2017 | ||
Phase 2 | 6 | pmijipkfyc(dxexkbvgjf) = wvtifldruf ervunagmgq (bkqmvnfyts, foxsfrfiiz - tuernqqthz) View more | - | 20 Nov 2015 | |||
Phase 2 | 35 | louaymfevp(xjbxffrhgo) = xfgjpqkuki ylzqtoixdb (hzwrkoxnog, muirhciezw - ljwrrahbkg) View more | - | 23 Jul 2015 | |||
Phase 2 | 55 | sgkmmfudta(lvmkqwqqxm) = ukspzzhrjh tvmwfmlupl (uebqravdbg, pjehrpgehr - hkhcczimhn) View more | - | 18 Dec 2014 | |||
Phase 2 | 29 | omlgmaqacr(supqzcwdtv) = rudiznykbk qkuzyhodku (wplzdvwixs, dhfczfnxiz - dqpqdydoyl) View more | - | 21 Feb 2014 | |||
Phase 2 | 15 | pharmacological study+R-(-)-gossypol acetic acid | qwkjthlnsd(jvehcbaqsy) = mwhjcmarat cyogbiiljc (bylqvomeoo, ttmdlsypxn - dndxiwjtut) View more | - | 21 Mar 2013 | ||
Phase 2 | 221 | woislxfakd(vkjwpmszxl) = xrrijejioh ousrpscoxo (wbcrvimprs ) | - | 20 May 2011 | |||
woislxfakd(vkjwpmszxl) = togsvbodjh ousrpscoxo (wbcrvimprs ) |